首页> 外文期刊>Breast cancer >Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
【24h】

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study

机译:校正至:埃布林和卡培他滨用于转移性乳腺癌的I期剂量确定研究:JBCRG-18开普研究

获取原文
           

摘要

The article “Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study”, written by Masaya Hattori, Hiroshi Ishiguro, Norikazu Masuda, Akiyo Yoshimura, Shoichiro Ohtani, Hiroyuki Yasojima, Satoshi Morita, Shinji Ohno, and Hiroji Iwata, was originally published electronically on the publisher’s Internet portal (currently SpringerLink) on 31 August 2017 without open access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on [9 November 2017] to ?.
机译:Masaya Hattori,Ishiguro Hiroshi,Norikazu Masuda,吉村明代,大谷昌一郎,安岛裕之,森田聪和岩田弘治(Hiroji Iwata)最初于2017年8月31日在发布者的互联网门户(现为SpringerLink)上以电子方式发布,但没有开放访问权限。由于作者决定选择“开放式选择”,文章的版权于[2017年11月9日]更改为?。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号